Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19

Taha, Muhanad; Sharma, Aditi; Soubani, Ayman O.

doi:10.1016/j.rmcr.2020.101231

Cited by 24 publications

(28 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, to reduce the risk of solid tumor patients in epidemic conditions, it is better for these patients not to develop neutropenia and to use Granulocyte Colony Stimulating Factor (G-CSFs) at the appropriate time [2,19].…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics of 60 Adult Cancer Patients Experience Covid-19: A Descriptive-Analytical Study

Aznab

Roozbahani

Moazen

2021

Preprint

View full text Add to dashboard Cite

Background This study aimed to describe the clinical symptoms, the severity of the disease, and survival status of COVID-19 cancer patients, and comparing the results in the different cancer subtypes and stages among various ages/sexes and techniques of treatment. Method: In a descriptive-analytical study, the clinical status of 60 cancer patients with a history of Covid-19 over the past year from the covid-19 pandemic in Iran (Jan. 2020-Dec.2020) was assessed. Results Most of the patients (68%) were in the solid tumor categories. The mean age of the men was 52 ± 13 years, and women were 47 ± 13 years (P < 0.05). Most cases of COVID-19 positive in solid tumor were breast cancer (24.4%), colon cancer (22%), gastric cancer (9.8%), and in hematologic malignancy, lymphoma (31.6%), chronic lymphocytic leukemia (CLL) (31.6%), and acute leukemia (21.1%). There was a statistically significant difference between two categories of cancer in the clinical manifestations; the stage of cancer and survival status (P < 0.05). Conclusion Based on our results risk factors for Covid-19 disease progression, severe pulmonary involvement, and fatal complications in patients with malignancy require further evaluation based on tumor type, stage, age, sex, and treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics of 60 Adult Cancer Patients Experience Covid-19: A Descriptive-Analytical Study

Aznab

Roozbahani

Moazen

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The risk factors that determine the progression of the disease in Covid-19 disease, severe pulmonary involvement, and more severe and fatal complications among patients with malignancy need further evaluation. However, to reduce the risk of solid tumor patients in epidemic conditions, it is better for these patients not to develop neutropenia and to use Granulocyte Colony Stimulating Factor (G-CSFs) at the appropriate time [2,19].…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics of 60 Adult Cancer Patients Experience Covid-19: A Descriptive-analytical Study

Aznab

Roozbahani

Moazen

2021

Preprint

View full text Add to dashboard Cite

Background: This study aimed to describe the clinical symptoms, the severity of the disease, and survival status of COVID-19 cancer patients, and comparing the results in the different cancer subtypes and stages among various ages/sexes and techniques of treatment.Method: In a descriptive-analytical study, the clinical status of 60 cancer patients with a history of Covid-19 over the past year from the covid-19 pandemic in Iran (Jan. 2020-Dec.2020) was assessed. Results: Most of the patients (68%) were in the solid tumor categories. The mean age of the men was 52 ± 13 years, and women were 47 ± 13 years (P<0.05). Most cases of COVID-19 positive in solid tumor were breast cancer (24.4%), colon cancer (22%), gastric cancer (9.8%), and in hematologic malignancy, lymphoma (31.6%), chronic lymphocytic leukemia (CLL) (31.6%), and acute leukemia (21.1%). There was a statistically significant difference between two categories of cancer in the clinical manifestations; the stage of cancer and survival status (P<0.05). Conclusion: Based on our results risk factors for Covid-19 disease progression, severe pulmonary involvement, and fatal complications in patients with malignancy require further evaluation based on tumor type, stage, age, sex, and treatment options.

show abstract

“…This recommendation is additionally supported by Pinada et al, who identify grade 4 neutropenia as a risk factor for COVID-19-related mortality [21]. There are however some concerns regarding the safety of G-CSF use due to the potential risk of them increasing exaggerated neutrophil responses; this can result in elevated secretion of inflammatory cytokines, thus worsening pulmonary infiltrations and exacerbating respiratory distress associated with adverse outcome [40][41][42]. According to the ESMO expert opinion, the risks associated with this strategy do not outweigh its benefits; however, until these issues are cleared, we recommend caution, and that the use of G-CSF should be avoided, or discontinued, in patients with respiratory infection, respiratory symptoms, or confirmed or suspected COVID-19 disease [39,43].…”

Section: General Prophylaxis Of Sars-cov-2 In Patients With Patients mentioning

confidence: 99%

The management of hematologic malignancies during the COVID-19 pandemic

Hus

Salomon-Perzyński

Tomasiewicz

et al. 2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19

Cited by 24 publications

References 13 publications

Clinical Characteristics of 60 Adult Cancer Patients Experience Covid-19: A Descriptive-Analytical Study

Clinical Characteristics of 60 Adult Cancer Patients Experience Covid-19: A Descriptive-Analytical Study

Clinical Characteristics of 60 Adult Cancer Patients Experience Covid-19: A Descriptive-analytical Study

The management of hematologic malignancies during the COVID-19 pandemic

Contact Info

Product

Resources

About